High-yield points
- LFS = germline TP53, autosomal dominant; many cancers, frequent second malignancies .
- CPC: about a third of tested children carry germline TP53. Test every child with CPC .
- Childhood SHH medulloblastoma with chromothripsis points to TP53. Germline TP53 explains more than half of chromothripsis in SHH medulloblastoma .
- LFS medulloblastoma does badly (5-year OS 23%), and radiotherapy improved survival in the largest cohort, the opposite of Gorlin syndrome .
- Toronto surveillance (whole-body MRI, brain MRI, ultrasound) was associated with 5-year OS of 89% vs 60% among carriers who developed cancer (observational) .
Landmark papers
- Toronto protocol (Villani et al., Lancet Oncol 2016): a prospective 11-year study of 89 TP53 carriers, 59 of whom underwent surveillance. Surveillance found 40 asymptomatic tumors in 19 of 59 patients (32%), and 5-year overall survival among carriers who developed cancer was 88.8% with surveillance vs 59.6% without (observational) .
- 2023 AACR update (Achatz et al., Clin Cancer Res 2025): the Toronto protocol remains the standard for lifelong surveillance, with tests changing by age, organ by organ .
Li-Fraumeni syndrome (LFS) results from a germline pathogenic or likely pathogenic TP53 variant and is inherited in an autosomal dominant pattern .
- Risk: a high lifetime risk of a broad range of cancers, and second malignancies are particularly common .
- Brain tumors are a core part of the spectrum. The neurosurgeon may be the first to suspect LFS from a child's tumor type.
Brain tumors that should prompt TP53 testing
- Choroid plexus carcinoma (CPC) :
- In a 20-year single-center series, 4 of 11 children with CPC tested (36.4%) carried a germline TP53 mutation.
- Overall, 6 of 42 choroid plexus tumor patients (16.7%) had features of LFS.
- Every child with CPC should be offered germline TP53 testing (see caveats).
- SHH medulloblastoma in childhood :
- Germline TP53 mutations occurred only in childhood (not infant) SHH medulloblastoma.
- They explained more than half (8 of 14) of the chromothripsis events in that subgroup.
- Chromothripsis, catastrophic one-step chromosome shattering, is strongly linked to TP53 mutation in SHH medulloblastoma .
- So a child (not an infant) with SHH medulloblastoma, especially with chromothripsis, needs germline TP53 testing.
- Medulloblastoma predisposition overall :
- germline mutations explained about 5–6% of medulloblastomas, and 14–20% of the SHH subgroup;
- the consensus predisposition genes are APC, BRCA2, PALB2, PTCH1, SUFU and TP53.
- High-grade gliomas and other tumors in a child with a strong family history of early cancers also warrant testing (see caveats).
Medulloblastoma in LFS: treatment and outcome
- Multinational cohort of 47 children :
- Subgroup: 86% were SHH_3, and 74% of the variants were missense.
- Survival is poor: 5-year PFS 20% and OS 23%.
- Radiotherapy helped, unlike in Gorlin syndrome:
- with postoperative radiotherapy: 2-year PFS 44%, OS 60%;
- without radiotherapy: 2-year PFS 0%, OS 25%.
- Chemotherapy intensity did not change outcome: high-intensity vs maintenance-type gave 2-year OS 68% vs 53%.
- The dilemma:
- radiation raises the risk of second cancers in TP53 carriers (see caveats);
- yet omitting it here was associated with worse survival .
- Decide in multidisciplinary tumor board with the family. Maximal safe resection remains the foundation (see caveats).
Surveillance (the "Toronto protocol")
- Prospective 11-year study :
- Cohort: 89 TP53 carriers; 59 underwent surveillance and the rest declined.
- Protocol: whole-body MRI, brain MRI, breast imaging, abdominal and pelvic ultrasound and colonoscopy.
- Asymptomatic tumors: surveillance found 40 in 19 of 59 patients (32%).
- 5-year overall survival among carriers who developed cancer: 88.8% with surveillance vs 59.6% without (an observational, as-treated comparison).
- 2023 AACR update :
- the Toronto protocol remains the standard for lifelong surveillance;
- which tests to use should change with age, organ by organ;
- the transition to adult surveillance is now defined in more detail.
- What this means for neurosurgery:
- annual brain MRI from infancy is part of standard LFS surveillance (see caveats);
- incidental lesions will be found;
- avoid CT where MRI will do.
Practical points for the neurosurgeon
- Take a three-generation family history for every child with a brain tumor:
- sarcoma;
- early breast cancer;
- adrenocortical carcinoma;
- brain tumors;
- leukemia.
- Test the germline in:
- CPC;
- childhood SHH medulloblastoma (especially with chromothripsis);
- any brain tumor with an LFS-type family history.
- If TP53-positive:
- involve genetics and oncology early;
- weigh radiation carefully;
- start surveillance;
- test relatives.
Related topics
- Medulloblastoma: Molecular Classification and Prognosis: SHH subgroup and chromothripsis.
- Pediatric High-Grade Glioma: another tumor in the LFS spectrum.
- Gorlin Syndrome: a predisposition syndrome where radiotherapy is avoided.
- Cowden Syndrome: another cancer-predisposition syndrome.
References
- Achatz MI, Villani A, Bertuch AA, et al. Update on cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res 2025;31(10):1831–1840. doi:10.1158/1078-0432.CCR-24-3301. PMID 40072304. verified
- Gozali AE, Britt B, Shane L, et al. Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991–2010. Pediatr Blood Cancer 2012;58(6):905–909. doi:10.1002/pbc.23349. PMID 21990040. verified
- Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 2018;19(6):785–798. doi:10.1016/S1470-2045(18)30242-030242-0). PMID 29753700. verified
- Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012;148(1–2):59–71. doi:10.1016/j.cell.2011.12.013. PMID 22265402. verified
- Kolodziejczak AS, Guerrini-Rousseau L, Planchon JM, et al. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro Oncol 2023;25(12):2273–2286. doi:10.1093/neuonc/noad114. PMID 37379234. verified
- Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 2016;17(9):1295–1305. doi:10.1016/S1470-2045(16)30249-230249-2). PMID 27501770. verified
Verification (2026-11-17):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
Caveats:
- The following are standard practice, not drawn from the cited abstracts:
- testing every child with CPC (reference 2 raises the question but does not recommend it);
- testing for high-grade glioma with a family history;
- the family-history list;
- maximal safe resection;
- the annual brain MRI and avoiding CT;
- radiation-induced second cancers in TP53 carriers.
- The Toronto protocol's exact schedule is in reference 6's full text.
- Reference 5 is retrospective, and the radiotherapy groups may differ in other ways.
- The figure is an original schematic.